Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Given Average Recommendation of “Hold” by Brokerages

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) have been assigned a consensus rating of “Hold” from the fifteen research firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, nine have assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $139.39.

ZBH has been the subject of several recent research reports. Raymond James boosted their price target on Zimmer Biomet from $133.00 to $137.00 and gave the company an “outperform” rating in a research note on Wednesday, January 3rd. Evercore ISI increased their target price on shares of Zimmer Biomet from $125.00 to $130.00 and gave the stock an “in-line” rating in a research report on Thursday, April 4th. JPMorgan Chase & Co. upped their price target on Zimmer Biomet from $115.00 to $125.00 and gave the stock a “neutral” rating in a research note on Friday, February 9th. Barclays upped their target price on Zimmer Biomet from $120.00 to $130.00 and gave the stock an “underweight” rating in a research report on Monday, February 12th. Finally, Truist Financial upped their price objective on shares of Zimmer Biomet from $133.00 to $135.00 and gave the stock a “hold” rating in a report on Friday, February 9th.

Zimmer Biomet Price Performance

Shares of NYSE:ZBH opened at $121.70 on Tuesday. The stock has a fifty day moving average of $125.92 and a 200-day moving average of $119.80. The company has a market capitalization of $25.00 billion, a PE ratio of 24.89, a price-to-earnings-growth ratio of 2.19 and a beta of 1.01. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.78 and a current ratio of 1.61. Zimmer Biomet has a one year low of $102.00 and a one year high of $149.25.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.15 by $0.05. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. The company had revenue of $1.94 billion during the quarter, compared to analyst estimates of $1.93 billion. During the same quarter in the prior year, the company earned $1.88 earnings per share. The company’s revenue for the quarter was up 6.3% on a year-over-year basis. As a group, equities analysts anticipate that Zimmer Biomet will post 8.07 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be issued a dividend of $0.24 per share. The ex-dividend date is Wednesday, March 27th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.79%. Zimmer Biomet’s payout ratio is presently 19.63%.

Insider Buying and Selling

In other news, VP Chad F. Phipps sold 26,156 shares of the firm’s stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total transaction of $3,364,184.72. Following the completion of the sale, the vice president now owns 44,145 shares of the company’s stock, valued at $5,677,929.90. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 0.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Zimmer Biomet

Institutional investors and hedge funds have recently bought and sold shares of the business. OLD Point Trust & Financial Services N A bought a new stake in Zimmer Biomet during the 4th quarter worth about $26,000. Ables Iannone Moore & Associates Inc. acquired a new position in Zimmer Biomet during the 4th quarter worth $30,000. Naples Money Management LLC bought a new stake in shares of Zimmer Biomet during the fourth quarter worth $35,000. Activest Wealth Management boosted its holdings in Zimmer Biomet by 410.4% in the fourth quarter. Activest Wealth Management now owns 342 shares of the medical equipment provider’s stock valued at $42,000 after acquiring an additional 275 shares during the last quarter. Finally, Peoples Bank KS bought a new stake in Zimmer Biomet during the 3rd quarter worth about $48,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.